Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) for determining prognosis in advanced stage hormone relapsing prostate cancer

Manish Kohli, Eric Siegel, Sudeepa Bhattacharya, Mir Alikhan Khan, Rajesh Shah, Larry J. Suva

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Prostate cancer frequently progresses despite early diagnosis and appropriate treatment with radical prostatectomy and/or radiotherapy. The clinical utility of SELDI-TOF MS to identify serum biomarker patterns associated with prostate cancer progression was examined by analysis of the serum proteome of advanced prostate cancer patients receiving standard androgen deprivation therapy. Serum from advanced-stage patients receiving androgen deprivation therapy was profiled by SELDI-TOF MS. Group 1 patients (n=15) had stable prostate specific antigen (PSA) responses to treatment; Group 2 (n=16) had rising PSA levels. Spectra were subjected to peak identification following total ion current (TIC) normalization. Peak intensities with m/z between 2,000 and 20,000 were tested for group differences via Kruskal-Wallis tests, and assessed individually for PSA-independent associations with overall survival via covariate-adjusted Cox regressions. TIC normalization yielded 53 useable spectra; 119 peaks with m/z between 2,000 and 20,000 were identified. Seven peaks showed statistically significant (p<0.05) differences between PSA groups, and several other peaks showed significant associations with overall survival independent of PSA status. In summary, SELDI-TOF MS captured a specific biomarker profile associated with biochemical relapse and provided additional prognostic information regarding long-term survival, independent of clinical PSA status.

Original languageEnglish (US)
Pages (from-to)249-258
Number of pages10
JournalCancer Biomarkers
Volume2
Issue number6
StatePublished - 2006
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Mass Spectrometry
Prostatic Neoplasms
Lasers
Hormones
Androgens
Survival
Biomarkers
Serum
Ions
Proteome
Therapeutics
Prostatectomy
Early Diagnosis
Radiotherapy
Recurrence

Keywords

  • Advanced disease
  • hormone-sensitive
  • prostatic neoplasm
  • proteomics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Genetics

Cite this

Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) for determining prognosis in advanced stage hormone relapsing prostate cancer. / Kohli, Manish; Siegel, Eric; Bhattacharya, Sudeepa; Khan, Mir Alikhan; Shah, Rajesh; Suva, Larry J.

In: Cancer Biomarkers, Vol. 2, No. 6, 2006, p. 249-258.

Research output: Contribution to journalArticle

Kohli, Manish ; Siegel, Eric ; Bhattacharya, Sudeepa ; Khan, Mir Alikhan ; Shah, Rajesh ; Suva, Larry J. / Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) for determining prognosis in advanced stage hormone relapsing prostate cancer. In: Cancer Biomarkers. 2006 ; Vol. 2, No. 6. pp. 249-258.
@article{65e034c39b6b4a98bad9ac162a000b06,
title = "Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) for determining prognosis in advanced stage hormone relapsing prostate cancer",
abstract = "Prostate cancer frequently progresses despite early diagnosis and appropriate treatment with radical prostatectomy and/or radiotherapy. The clinical utility of SELDI-TOF MS to identify serum biomarker patterns associated with prostate cancer progression was examined by analysis of the serum proteome of advanced prostate cancer patients receiving standard androgen deprivation therapy. Serum from advanced-stage patients receiving androgen deprivation therapy was profiled by SELDI-TOF MS. Group 1 patients (n=15) had stable prostate specific antigen (PSA) responses to treatment; Group 2 (n=16) had rising PSA levels. Spectra were subjected to peak identification following total ion current (TIC) normalization. Peak intensities with m/z between 2,000 and 20,000 were tested for group differences via Kruskal-Wallis tests, and assessed individually for PSA-independent associations with overall survival via covariate-adjusted Cox regressions. TIC normalization yielded 53 useable spectra; 119 peaks with m/z between 2,000 and 20,000 were identified. Seven peaks showed statistically significant (p<0.05) differences between PSA groups, and several other peaks showed significant associations with overall survival independent of PSA status. In summary, SELDI-TOF MS captured a specific biomarker profile associated with biochemical relapse and provided additional prognostic information regarding long-term survival, independent of clinical PSA status.",
keywords = "Advanced disease, hormone-sensitive, prostatic neoplasm, proteomics",
author = "Manish Kohli and Eric Siegel and Sudeepa Bhattacharya and Khan, {Mir Alikhan} and Rajesh Shah and Suva, {Larry J.}",
year = "2006",
language = "English (US)",
volume = "2",
pages = "249--258",
journal = "Cancer Biomarkers",
issn = "1574-0153",
publisher = "IOS Press",
number = "6",

}

TY - JOUR

T1 - Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) for determining prognosis in advanced stage hormone relapsing prostate cancer

AU - Kohli, Manish

AU - Siegel, Eric

AU - Bhattacharya, Sudeepa

AU - Khan, Mir Alikhan

AU - Shah, Rajesh

AU - Suva, Larry J.

PY - 2006

Y1 - 2006

N2 - Prostate cancer frequently progresses despite early diagnosis and appropriate treatment with radical prostatectomy and/or radiotherapy. The clinical utility of SELDI-TOF MS to identify serum biomarker patterns associated with prostate cancer progression was examined by analysis of the serum proteome of advanced prostate cancer patients receiving standard androgen deprivation therapy. Serum from advanced-stage patients receiving androgen deprivation therapy was profiled by SELDI-TOF MS. Group 1 patients (n=15) had stable prostate specific antigen (PSA) responses to treatment; Group 2 (n=16) had rising PSA levels. Spectra were subjected to peak identification following total ion current (TIC) normalization. Peak intensities with m/z between 2,000 and 20,000 were tested for group differences via Kruskal-Wallis tests, and assessed individually for PSA-independent associations with overall survival via covariate-adjusted Cox regressions. TIC normalization yielded 53 useable spectra; 119 peaks with m/z between 2,000 and 20,000 were identified. Seven peaks showed statistically significant (p<0.05) differences between PSA groups, and several other peaks showed significant associations with overall survival independent of PSA status. In summary, SELDI-TOF MS captured a specific biomarker profile associated with biochemical relapse and provided additional prognostic information regarding long-term survival, independent of clinical PSA status.

AB - Prostate cancer frequently progresses despite early diagnosis and appropriate treatment with radical prostatectomy and/or radiotherapy. The clinical utility of SELDI-TOF MS to identify serum biomarker patterns associated with prostate cancer progression was examined by analysis of the serum proteome of advanced prostate cancer patients receiving standard androgen deprivation therapy. Serum from advanced-stage patients receiving androgen deprivation therapy was profiled by SELDI-TOF MS. Group 1 patients (n=15) had stable prostate specific antigen (PSA) responses to treatment; Group 2 (n=16) had rising PSA levels. Spectra were subjected to peak identification following total ion current (TIC) normalization. Peak intensities with m/z between 2,000 and 20,000 were tested for group differences via Kruskal-Wallis tests, and assessed individually for PSA-independent associations with overall survival via covariate-adjusted Cox regressions. TIC normalization yielded 53 useable spectra; 119 peaks with m/z between 2,000 and 20,000 were identified. Seven peaks showed statistically significant (p<0.05) differences between PSA groups, and several other peaks showed significant associations with overall survival independent of PSA status. In summary, SELDI-TOF MS captured a specific biomarker profile associated with biochemical relapse and provided additional prognostic information regarding long-term survival, independent of clinical PSA status.

KW - Advanced disease

KW - hormone-sensitive

KW - prostatic neoplasm

KW - proteomics

UR - http://www.scopus.com/inward/record.url?scp=34248562033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248562033&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 249

EP - 258

JO - Cancer Biomarkers

JF - Cancer Biomarkers

SN - 1574-0153

IS - 6

ER -